Eli Lilly and Company reports $65.18 billion revenue for fiscal year ended December 31, 2025, up 44.7%

ยท LLY

Eli Lilly and Company reported revenue of $65.18 billion for the year ended December 31, 2025, an increase of 44.7% from the previous year ($45.04 billion).

For the same period it posted net income of $20.64 billion, up 94.9%, or $22.95 per diluted share (11.71 a year earlier).

That is a net margin of 31.7%.

On Sanad's AAOIFI Standard 21 screen, Eli Lilly and Company is currently compliant: interest-bearing debt is 3.7% of market capitalisation (limit 30%), and impure income is 0.2% of revenue (limit 5%).

Source: 10-K filed with the U.S. Securities and Exchange Commission on February 12, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.

More Eli Lilly and Company news